One might surmise that by the time FDA asks an advisory committee to vet an application, the questions would deal primarily with clinical utility.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.Â
